Eversept Partners’s UroGen Pharma URGN Stock Holding History

Eversept Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-74,797	Closed	-$774K	–	77
2023 Q2	$774K	Buy	+74,797	New	+$825K	0.06%	66

Other funds holding URGN

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Eversept Partners's URGN Position: Q3 2023 in Review

Eversept Partners sold out of UroGen Pharma (URGN) in Q3 2023, closing a stake of 74,797 shares — an estimated $774K sold.

Eversept Partners first reported a position in URGN in Q2 2023 and held it in 1 quarter. The position peaked at $774K in Q2 2023. 101 funds tracked by Wall St. Rank hold URGN as of Q3 2023.

Eversept Partners reported no remaining UroGen Pharma position as of Q3 2023 after selling out during the quarter.
Eversept Partners sold 74,797 UroGen Pharma shares in Q3 2023, an estimated $774K.
Eversept Partners first reported a position in UroGen Pharma in Q2 2023 and held it in 1 quarter.
Eversept Partners's UroGen Pharma position peaked at $774K in Q2 2023.
101 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2023.

Based on Eversept Partners's 13F filing for Q3 2023, filed 14 Nov 2023.